指南与共识浆细胞疾病

欧洲骨髓瘤网络关于功能性高危多发性骨髓瘤的共识声明

European Myeloma Network Consensus Statement on Functional High-Risk Multiple Myeloma.
指南 / 共识 · Am J Hematol · 2025-09-09

该共识将功能性高危多发性骨髓瘤(FHR-MM)定义为一线治疗开始后18个月内疾病进展且无高危细胞遗传学异常,讨论其疾病生物学并探讨改善此类患者结局的策略。

要点

  • FHR-MM定义为一线治疗开始后18个月内进展且无高危细胞遗传学异常。
  • 约20%的新诊断多发性骨髓瘤患者虽诊断时未预测为高危,仍早期进展。
  • 基于新药诱导治疗的缓解深度与持续时间尚未被定义为疾病风险的动态标志。

核心结论

  • 无论诊断时风险分层如何,基于新药诱导治疗的缓解可能是识别功能性高危生物学患者的最有效方法,这类患者的总生存期过短。

研究设计与样本

  • 欧洲骨髓瘤网络(EMN)制定的共识声明。

主要发现

  • 约20%的新诊断多发性骨髓瘤患者诊断时未预测为高危,尽管接受 optimal 诱导联合或不联合自体造血干细胞移植及来那度胺维持治疗,仍早期进展,随后被归类为功能性高危(FHR)疾病。

关键数值与推荐

  • FHR-MM定义为一线治疗开始后18个月内疾病进展且无高危细胞遗传学异常。
  • 标准化风险分层模型纳入肿瘤负荷生物标志物、高危细胞遗传学存在与否以及浆细胞白血病/髓外疾病的有无来归因诊断时高危。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is an incurable blood cancer characterized by clonal bone marrow plasmacytosis, hypercalcemia, renal failure, anemia, and osteolytic bone disease. Approximately 20% of NDMM patients, not predicted to have high-risk disease at diagnosis, progress early, despite optimal induction +/- ASCT and lenalidomide maintenance, and are subsequently categorized as functional high-risk (FHR) disease. Standardized risk-stratification models incorporate biomarkers of tumor burden, existence of high-risk cytogenetics, with the presence/absence of plasma cell leukemia/extramedullary disease to attribute high-risk at diagnosis; however, depth/duration of response to novel agent-based induction (NA-IND) as dynamic markers of disease risk have not been defined. However, irrespective of diagnostic risk-stratification, response to NA-IND may be the single most effective method of identifying patients whose FHR biology portends an unacceptably short overall survival (OS). In this EMN consensus statement, we define FHR-MM as disease progression within 18 months of commencement of first-line therapy in the absence of high-risk cytogenetics, discuss the underlying disease biology, and strategies to improve outcomes for these patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Lim SL, Engelhardt M, Terpos E, et al. European Myeloma Network Consensus Statement on Functional High-Risk Multiple Myeloma. Am J Hematol. 2025. PMID: 40926508. doi:10.1002/ajh.70070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。